Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: N/A
- Sub-Industry: N/A
- Symbol: FRA:MRK
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: €104.32
- 200 Day Moving Avg: €104.63
- Trailing P/E Ratio: 25.98
- P/E Growth: 3.26
Frequently Asked Questions for Merck KGaA (FRA:MRK)
What is Merck KGaA's stock symbol?
Merck KGaA trades on the FRA under the ticker symbol "MRK."
Where is Merck KGaA's stock going? Where will Merck KGaA's stock price be in 2017?
23 brokerages have issued 12-month price targets for Merck KGaA's shares. Their forecasts range from €95.00 to €128.00. On average, they anticipate Merck KGaA's stock price to reach €109.55 in the next year. View Analyst Ratings for Merck KGaA.
Who are some of Merck KGaA's key competitors?
MarketBeat Community Rating for Merck KGaA (FRA MRK)MarketBeat's community ratings are surveys of what our community members think about Merck KGaA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Some companies that are related to Merck KGaA include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Merck KGaA (MKGAY), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), ConvaTec Group PLC (CTEC), Mediclinic International PLC (MDC), Health Net (HNT), Patheon NV (PTHN), NMC Health PLC (NMC), Catalent (CTLT), Cotiviti Holdings (COTV), Puma Biotechnology (PBYI), Hikma Pharmaceuticals Plc (HIK) and WuXi PharmaTech (Cayman) (WX).
Consensus Ratings for Merck KGaA (FRA:MRK) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||2 Sell Ratings, 16 Hold Ratings, 5 Buy Ratings|
|Consensus Rating:||Hold (Score: 2.13)|
|Consensus Price Target: ||€109.55|
Analysts' Ratings History for Merck KGaA (FRA:MRK)
(Data available from 7/28/2015 forward)
|7/27/2017||Goldman Sachs Group, Inc. (The)||Set Price Target||Neutral||€110.00|
|7/26/2017||Credit Suisse Group||Set Price Target||Neutral||€106.00|
|7/26/2017||Deutsche Bank AG||Set Price Target||Neutral||€106.00|
|7/26/2017||J P Morgan Chase & Co||Set Price Target||Neutral||€100.00|
|7/26/2017||Berenberg Bank||Set Price Target||Neutral||€110.00|
|7/18/2017||DZ Bank AG||Reiterated Rating||Sell|
|7/7/2017||Warburg Research||Set Price Target||Neutral||€116.00|
|6/26/2017||Independent Research GmbH||Set Price Target||Neutral||€115.00|
|6/26/2017||Morgan Stanley||Set Price Target||Neutral||€103.00|
|6/26/2017||equinet AG||Set Price Target||Neutral||€112.00|
|6/13/2017||Commerzbank Ag||Set Price Target||Neutral||€109.00|
|6/1/2017||Kepler Capital Markets||Set Price Target||Buy||€128.00|
|5/20/2017||BNP Paribas||Set Price Target||Buy||€114.00|
|5/19/2017||S&P Global||Set Price Target||Neutral||€115.00|
|4/10/2017||Citigroup Inc.||Set Price Target||Buy||€116.00|
|4/7/2017||HSBC Holdings plc||Set Price Target||Sell||€95.00|
|3/24/2017||Sanford C. Bernstein||Set Price Target||Neutral||€109.00|
|3/23/2017||Societe Generale||Set Price Target||Neutral||€105.00|
|11/30/2016||Bank of America Corporation||Set Price Target||Buy||€115.00|
|11/15/2016||Bankhaus Lampe||Set Price Target||Buy||€112.00|
|11/15/2016||S&P Global Inc.||Set Price Target||Neutral||€103.00|
|8/5/2016||Baader Bank||Set Price Target||Neutral||€97.00|
|5/10/2016||Barclays PLC||Set Price Target||Neutral||€87.00|
|12/11/2015||S&P Equity Research||Set Price Target||Neutral||€104.00|
Earnings History for Merck KGaA (FRA:MRK)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Merck KGaA (FRA:MRK)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Merck KGaA (FRA:MRK)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Merck KGaA (FRA:MRK)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Merck KGaA (FRA:MRK)
Latest Headlines for Merck KGaA (FRA:MRK)